Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
暂无分享,去创建一个
C. Mullighan | M. Konopleva | H. Kantarjian | G. Garcia-Manero | S. Verstovsek | Xuelin Huang | K. Patel | T. Kadia | F. Ravandi | Koichi Takahashi | E. Jabbour | N. Daver | C. Dinardo | S. O'brien | J. Khoury | N. Pemmaraju | N. Jain | N. Short | J. Jorgensen | Sa A. Wang | R. Champlin | K. Roberts | P. Kebriaei | I. Khouri | Y. Alvarado | K. Sasaki | Feng Wang | Yuya Sasaki | G. Issa | Maria R. Khouri | Guillaume Richard-Carpentier | Zhaohui Gu | Heather M Schroeder
[1] H. Kantarjian,et al. Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management , 2019, Cancer.
[2] R. Larson,et al. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study , 2019, Cancer.
[3] M. Konopleva,et al. Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia , 2019, Blood.
[4] D. Leongamornlert,et al. Prognostic Impact of Chromosomal Abnormalities and Copy Number Alterations Among Adults with B-Cell Precursor Acute Lymphoblastic Leukaemia Treated on UKALL14 , 2019, Blood.
[5] M. Konopleva,et al. Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL) , 2019, Blood.
[6] M. Konopleva,et al. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survival , 2019, American journal of hematology.
[7] M. Konopleva,et al. Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis , 2019, Cancer.
[8] C. Bloomfield,et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. , 2019, Blood.
[9] C. Pui,et al. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia , 2018, JAMA oncology.
[10] H. Dombret,et al. Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] H. Dombret,et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. , 2018, Blood.
[12] T. Klausen,et al. Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia , 2018, Leukemia.
[13] M. Konopleva,et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. , 2018, The Lancet. Oncology.
[14] C. Mullighan,et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. , 2017, Blood.
[15] M. Loh,et al. Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] H. Dombret,et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.
[17] M. Konopleva,et al. Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimen , 2016, American journal of hematology.
[18] J. Bourhis,et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. , 2015, Blood.
[19] Heather L. Mulder,et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.
[20] B. Leber,et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia , 2014, Leukemia.
[21] W. Wierda,et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. , 2011, Blood.
[22] M. Andreeff,et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] H. Dombret,et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia , 2010, Haematologica.
[24] N. Heisterkamp,et al. Pre–B cell receptor–mediated cell cycle arrest in Philadelphia chromosome–positive acute lymphoblastic leukemia requires IKAROS function , 2009, The Journal of experimental medicine.
[25] H. Kantarjian,et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. , 2009, Blood.
[26] G. Basso,et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. , 2008, Blood.
[27] M. Tormo,et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] P. Parren,et al. The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201 , 2006, The Journal of Immunology.
[29] Peter F Thall,et al. Monitoring event times in early phase clinical trials: some practical issues , 2005, Clinical trials.
[30] P. Thall,et al. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.
[31] D. Hoelzer,et al. Chemoimmunotherapy in acute lymphoblastic leukemia. , 2012, Blood reviews.